Lercanidipin Heumann

Lercanidipine, the active ingredient in Lercanidipin Heumann, is a calcium channel blocker presented as a tablet for oral use. It treats hypertension in adult patients by lowering blood pressure.

GNH USA supplies Lercanidipin Heumann as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a calcium channel blocker used to manage elevated blood pressure within the antihypertensive drug class.

Essential hypertension: reduces systolic and diastolic blood pressure, improving cardiovascular risk profile. Primary hypertension: provides sustained blood pressure control when lifestyle measures are insufficient. Secondary hypertension (e.g., renal or endocrine causes): assists in achieving target pressures alongside treatment of the underlying condition.

Lercanidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warmth and redness, typically occurring shortly after dosing. - Peripheral edema: swelling of the ankles or feet due to fluid accumulation. - Dizziness or light‑headedness, especially when standing quickly. - Tachycardia: an increase in heart rate that may accompany vasodilation. - Fatigue: general feeling of tiredness without a clear cause.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure leading to fainting or shock. - Myocardial infarction: rare occurrence of heart attack symptoms. - Hepatic injury: signs of liver dysfunction such as jaundice or elevated enzymes. - Allergic reactions: rash, pruritus, or anaphylaxis requiring urgent care.

Before initiating therapy with Lercanidipine, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Blood pressure monitoring: check baseline and periodic readings to assess efficacy and avoid excessive hypotension. - Cardiac assessment: review history of heart failure or ischemic disease before use. - Concomitant antihypertensives: adjust doses of other blood‑pressure agents to prevent additive effects. - Hepatic function: use caution in patients with moderate to severe liver impairment. - Discontinuation: avoid abrupt cessation; taper if long‑term therapy is stopped. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations and risk of toxicity. - Grapefruit juice: can markedly raise lercanidipine levels, leading to hypotension. - Other calcium‑channel blockers: additive vasodilatory effects may cause severe hypotension.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance blood‑pressure‑lowering effect, requiring dose adjustments. - Beta‑blockers: combined use can lead to excessive heart‑rate reduction. - ACE inhibitors or ARBs: monitor renal function and electrolytes for additive effects. - NSAIDs: may blunt antihypertensive response, necessitating closer blood‑pressure monitoring.